Propel(x) is a Franklin Templeton Evo Nexus Incubator Portfolio Company
Vaccine development in general on average takes 8-15 years. So even the talk about having a vaccine in the next 12-18 months since the pandemic started is breathtakingly optimistic.
Considering the challenges and complications around developing a coronavirus vaccine, when COVID-19 vaccine is finally ready, will the world be? How safe and efficient will this vaccine be?
Join us in a panel discussion with life sciences experts from academia and venture capital to hear how the industry is trying to work towards a solution and achieve a shared global goal of identifying a potential cure for COVID-19. Watch replay below.
Moderated by Hemai Parthasarathy from Breakout Ventures, speakers include John Lewis from University of Alberta, Una Ryan from Golden Seeds and Jenny Yip from Adjuvant Capital.
This meeting is for informational purposes only. It is not a solicitation or offer to purchase or sell any security, nor should this information be construed as advice for investment decisions.
Private Placements are a high-risk investment. An investment in this offering is speculative and an investor could experience an entire loss of principal. Private investments are highly illiquid and risky and are not suitable for all investors. There is no guarantee that an investment will be profitable or that there will ever be an exit strategy or an opportunity to liquidate the investment. Investments in early-stage private companies should only be part of your overall investment portfolio.
Propel(x) is a Franklin Templeton Evo Nexus Incubator Portfolio Company
This site is operated by Propel(x) Inc. (“Propel(x)”), which is not a registered broker dealer. Propel(x) does not give investment advice, endorsement, analysis or recommendations with respect to any securities. All securities posted here are being offered by, and all information included on this site is the responsibility of the issuer of such securities. Propel(x) has not taken steps to verify the adequacy, accuracy, or completeness of the information. Neither Propel(x) nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind related to the adequacy, accuracy or completeness of any information on this site or the use of information on this site. By accessing this site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy.
This Website is intended solely for accredited investors. Private Investments are highly risky and are not suitable for all investors. Investments in early-stage private companies should only be part of your overall investment portfolio. Furthermore, the allocation to this asset sub-class may be best fulfilled through a balanced portfolio of diversified startups. Investments in startups are highly illiquid and those investors who cannot hold an investment for the long term (at least 5-7 years) should not invest. There is no guarantee that an investment will be profitable. All investments bear the risk of partial or complete loss of capital. Please review risk factors for investments on Propel(x) here.
Certain opportunities posted on the platform and so designated are advised by Planck Fund Management Corporation (“PFMC”), an affiliate of Propel(x), located at 1 Franklin Parkway, Bldg # 930/1 – Fintech Suite, San Mateo CA 94403. PFMC does not make investment recommendations and no communication, through this website or in any other medium should be construed as a recommendation for any security offered on or off this investment platform.
Brokerage products and services offered by Hubble Investments, Member FINRA – https://www.finra.org/about and SIPC https://www.sipc.org/ an
©2023 Propel(x). All rights reserved. Various trademarks held by their respective owners.
